Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of prexasertib in recurrent platinum-resistant or platinum-refractory ovarian cancer
MOH_2018-03-07_002024Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of prexasertib in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (4 arms), sponsored by Eli Lilly and Company. Started Jan 2018; status: active, not recruiting.
02
Drugs
prexasertib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on MOH_2018-03-07_002024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-03-07_002024.